2019年美国临床肿瘤学年会-肝癌会议热点

2019-05-30 不详 网络

2019年美国临床肿瘤学会年会(ASCO)将于2019年5月31日—6月4日,在美国芝加哥召开。近年来,ASCO年会一直是全球肿瘤界最大的年度聚会,届时来自世界各地的38000多名与会者、32000多名医疗专业人士以及500家展商将汇聚于此,共享此次肿瘤届年度盛宴!

2019年美国临床肿瘤学会年会(ASCO)将于2019年5月31日—6月4日,在美国芝加哥召开。近年来,ASCO年会一直是全球肿瘤界最大的年度聚会,届时来自世界各地的38000多名与会者、32000多名医疗专业人士以及500家展商将汇聚于此,共享此次肿瘤届年度盛宴!

点击图片,查看2019 ASCO 结直肠癌&胃肠道间质瘤会议热点

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069770, encodeId=8e862069e7069, content=<a href='/topic/show?id=26f6e972596' target=_blank style='color:#2F92EE;'>#美国临床肿瘤学年会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79725, encryptionId=26f6e972596, topicName=美国临床肿瘤学年会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jun 20 06:50:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390788, encodeId=05061390e881f, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Jun 01 02:50:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040194, encodeId=1d2a104019488, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu May 30 14:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069770, encodeId=8e862069e7069, content=<a href='/topic/show?id=26f6e972596' target=_blank style='color:#2F92EE;'>#美国临床肿瘤学年会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79725, encryptionId=26f6e972596, topicName=美国临床肿瘤学年会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jun 20 06:50:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390788, encodeId=05061390e881f, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Jun 01 02:50:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040194, encodeId=1d2a104019488, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu May 30 14:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2069770, encodeId=8e862069e7069, content=<a href='/topic/show?id=26f6e972596' target=_blank style='color:#2F92EE;'>#美国临床肿瘤学年会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79725, encryptionId=26f6e972596, topicName=美国临床肿瘤学年会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Thu Jun 20 06:50:00 CST 2019, time=2019-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390788, encodeId=05061390e881f, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sat Jun 01 02:50:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040194, encodeId=1d2a104019488, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu May 30 14:50:00 CST 2019, time=2019-05-30, status=1, ipAttribution=)]
    2019-05-30 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

2019年美国临床肿瘤学年会-结直肠癌&胃肠道间质瘤会议热点

2019年美国临床肿瘤学会年会(ASCO)将于2019年5月31日—6月4日,在美国芝加哥召开。近年来,ASCO年会一直是全球肿瘤界最大的年度聚会,届时来自世界各地的38000多名与会者、32000多名医疗专业人士以及500家展商将汇聚于此,共享此次肿瘤届年度盛宴!